The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.

The design and profile of a series of indole containing long acting beta(2)-adrenoceptor agonists is described. Evaluation of these analogues using an in vitro guinea pig trachea tissue model demonstrates that analogues within this series have salmeterol-like duration of action with potential for long duration of action in humans.

[1]  J. Lötvall,et al.  Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.

[2]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[3]  K. Osterberg,et al.  Steric aspects of agonism and antagonism at beta-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. , 1991, Chirality.

[4]  A. Tattersfield,et al.  The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. , 1999, The European respiratory journal.

[5]  R. A. Coleman,et al.  Investigations into factors determining the duration of action of the β2‐adrenoceptor agonist, salmeterol , 1993, British journal of pharmacology.

[6]  G. Anderson.  Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.

[7]  K. Rabe,et al.  Why are long-acting beta-adrenoceptor agonists long-acting? , 1994, The European respiratory journal.

[8]  Alan Daniel Brown,et al.  The discovery of long acting β2-adrenoreceptor agonists , 2007 .

[9]  R. Austin,et al.  QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. , 2003, Journal of medicinal chemistry.

[10]  A. Taburet,et al.  Pharmacokinetic Optimisation of Asthma Treatment , 1994, Clinical pharmacokinetics.

[11]  M. Johnson,et al.  The pharmacology of salmeterol. , 1993, Life sciences.

[12]  Paul A. Glossop,et al.  Progress in the Development of Inhaled, Long-Acting β2-Adrenoceptor Agonists , 2006 .

[13]  B. Waldeck.  Beta-adrenoceptor agonists and asthma--100 years of development. , 2002, European journal of pharmacology.